"Our product isn’t going to be an AI model. Our product isn’t going to be a cool new technology. It’s going to be actual medicines that save lives," Singh tells a room full of policy makers, investors ...
Background: Determining optimal timing for intensifying the frequency of physician encounters for type 2 diabetes mellitus (T2DM) requires trade-offs between timely care and clinician burden. We aimed ...